Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Boston Scientific Corporation (BSX) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Boston Scientific CorporationTrade
First Citizens BancShares IncTrade

Price performance (Past 24H)

Key statistics

Boston Scientific Corporation vs First Citizens BancShares Inc — how do they compare? Boston Scientific Corporation trades at $51.41 (market cap $74.52B), while First Citizens BancShares Inc trades at $2,273.65 (market cap $25.26B). The key difference: Boston Scientific Corporation is far larger — about 3× First Citizens BancShares Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.

BSXFCNCA
Market Cap
$74.52B$25.26B
Sector
HealthSector/Thematic
52-Week High
$108.14$2.27K
52-Week Low
$42.63$1.64K
Enterprise Value
$86.60B
Dividend Yield
0.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Boston Scientific Corporation

Boston Scientific (BSX) trades at $51.66, up 2.38% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical signals with moving averages supporting upward movement, though oscillators indicate potential overbought conditions. Fundamentally, BSX demonstrates robust growth with 2025 revenue reaching $20.07B and net income margin expanding to 14.43%, supported by strong cash flow generation of $1.54B in 2025.

The outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target offering 30% upside potential. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with recent guidance cuts. Insider buying by the CEO and director signals management confidence in the company's long-term prospects despite near-term challenges.

First Citizens BancShares Inc

First Citizens BancShares (FCNCA) trades at $2,271.31, up 1.7% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by consistent revenue around $9.3B. Recent news highlights expansion in commercial lending and strategic leadership appointments, reinforcing growth initiatives.

Outlook remains positive due to earnings momentum and dividend stability, but risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is cautious with 82% hold ratings, suggesting limited near-term upside despite a $2,310 price target. Investors should weigh solid profitability against sector headwinds and valuation constraints.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Boston Scientific Corporation

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Read more on BSX

About First Citizens BancShares Inc

First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.

Read more on FCNCA